AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Heidelberg Pharma AG

Declaration of Voting Results & Voting Rights Announcements Jul 6, 2010

201_dva_2010-07-06_fe05fff3-bf5b-4c57-be17-75d762d81f44.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

News Details

Voting Rights Announcements | 6 July 2010 10:03

WILEX AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

WILEX AG / Release of an announcement according to Article 27a Section 1 of the WpHG

06.07.2010 10:03

Dissemination of a Voting Rights announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.


Convenience Translation

dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, announced in
a notice dated 4 June 2010 that its shareholdings had surpassed the
threshold of 30% on 2 June 2010. Pursuant to section 22 para. 1 sentence 1
no. 1 German Securities Trading Act, the voting shares are attributable to
the following companies and individuals, some of whom are holding a small
number of additional shares and informed the Company of their purchases of
voting shares in the respective notices dated 4 June 2010:

  1. DH-Capital GmbH & Co. KG, Wiesloch, Germany;

  2. Verwaltungsgesellschaft des Golf Club St. Leon-Rot GmbH, St. Leon-Rot,
    Germany;

  3. Oliver Hopp, Germany;

  4. OH Beteiligungen GmbH & Co. KG, Wiesloch, Germany;

  5. BW Verwaltungs GmbH, Wiesloch, Germany;

  6. Golf Club St. Leon-Rot Betriebsgesellschaft mbH & Co. KG, St. Leon-Rot,
    Germany;

  7. Dietmar Hopp, Germany;

  8. OH-Capital GmbH & Co. KG, Wiesloch, Germany; as well as

  9. Berthold Wipfler, Germany.

By notification dated 2 July 2010, both dievini Hopp BioTech holding GmbH &
Co. KG and the persons specified in foregoing item 1 through 9 above
(hereinafter 'dievini') informed the Company of the following in accordance
with section 27a para. 1 German Securities Trading Act concerning the aims
underlying the purchase of the voting rights and the origin of the funds
used to purchase the voting rights:

The notification threshold of 30% was surpassed by means of stock purchases
in OTC trading.

I. dievini continues to pursue its long-term strategic commitment to the
issuer and is not interested in achieving short-term gains from trading.

II. As announced on 4 June 2010, in the next few days dievini will make an
offer to purchase all shares held by WILEX AG's outside shareholders in
accordance with section 35 German Securities Acquisition and Takeover Act;
dievini will also be prepared to subscribe shares in connection with an
imminent capital increase. Whilst dievini does not have any concrete plans
at this time to acquire additional voting shares through purchases or other
means within the next 12 months, the company is basically interested in
seeing WILEX evolve. As a result, dievini will review strategic options
regarding the Company and/or its products and product candidates as they
arise and, if necessary, weigh modifying its equity interest, including by
means of additional purchases, should such opportunities arise.

III. dievini is represented by two individuals on the Company's Supervisory
Board - Prof. Dr Friedrich von Bohlen und Halbach (since 2005) and
Professor Christof Hettich (since the Company's recent 2010 Annual General
Meeting). In addition, dievini also wants to use the power it has gained
through its shareholdings to influence appointments to the issuer's
administrative, management and supervisory bodies.

IV. At this time, dievini is not planning any major change in the Company's
capital structure, particularly with respect to the ratio of equity and
borrowings, and its dividend policies. What applies in this regard too is
that dievini is basically interested in seeing WILEX evolve, which is why
dievini will review all strategic options regarding the Company and/or its
products and product candidates as they arise and, if necessary, weigh
changing the capital structure.

V. The funds used to purchase the voting rights were financed by dievini's
own resources.

Munich, 6 July 2010

WILEX AG
The Executive Management Board

06.07.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Internet: www.wilex.com

End of News DGAP News-Service


Talk to a Data Expert

Have a question? We'll get back to you promptly.